Intraocular pressure was measured between 10:00h and 12:00h at baseline, 4 weeks and 12 weeks. Patients with open angle glaucoma or ocular hypertension controlled on Xalatan qHS and Timoptic XE 0.5% qAM were randomized to either continue their current therapy (UFC, n=25) or to switch to Xalacom qHS (FC, n=24). Methods: This was a single masked randomized controlled trial. The secondary objective was to compare compliance, safety and patient satisfaction between the two regimens. Purpose: The purpose of this study was to compare the intraocular pressure–lowering efficacy of Xalacom TM fixed–combination therapy (FC) to Xalatan TM combined with Timoptic XE TM 0.5% unfixed combination (UFC) in the treatment of chronic open angle glaucoma or ocular hypertension.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |